BrainStorm, FDA map out next steps for Phase 3b testing of NurOwn
BrainStorm Cell Therapeutics has had a meeting with the U.S. Food and Drug Administration (FDA) seeking an agreement on…
Articles by Margarida Maia, PhD
Coya, Dr. Reddy’s collaborate to advance COYA 302 for ALS
Under a new agreement, Coya Therapeutics’ amyotrophic lateral sclerosis (ALS) treatment candidate COYA 302 — which aims to suppress…
PrimeC safe, shows trends toward slowing ALS progression: Trial data
NeuroSense Therapeutics’ PrimeC was found to be safe and well tolerated in a Phase 2b trial, and use of the…
Anxiety high in ALS patients, family members in months after diagnosis
Anxiety is common among people newly diagnosed with amyotrophic lateral sclerosis (ALS) and their family members, a small study…
Gene variant may advance ALS onset by about 3 years: Study
A particular genetic variant that boosts the activity of the NEAT1 gene can push the onset of amyotrophic lateral…
Rapamycin fails to raise regulatory T-cell levels in RAP-ALS trial
Rapamycin, an approved medication used to prevent organ rejection after a kidney transplant, didn’t increase the number of regulatory…
Spinogenix awarded $1M to advance clinical testing of SPG302
Spinogenix has won a nearly $1 million grant from the U.S. Department of Defense (DoD) to move ahead with…
Dosing of healthy adults begins in Phase 1 study of oral CVN293
A first healthy volunteer has been dosed in a Phase 1 clinical study evaluating how safe and well tolerated is…
New deal aims to bring edaravone for ALS to Australia, New Zealand
Note: This story was updated Sept. 25, 2023, to correct that TW001 uses the same active ingredient as Radicava and…
More evidence needed to support use of high-calorie diet for ALS
While eating a high-calorie diet is safe and well tolerated, it does not appear to slow disease progression or reduce…